Skip to content

PACE Cognition Proof-of-Concept Study

Impact of Physiologic Pacemaker Programming on Cognitive Function and Health Status in Patients With Symptomatic Bradycardia

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07769424
Enrollment
110
Registered
2026-08-18
Start date
2026-10-01
Completion date
2028-10-01
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Function, Health Status, Pacemaker, Symptomatic Bradycardia

Keywords

PACE Cognition, Symptomatic bradycardia, Physiologic pacing, Pacemaker programming, myPACE algorithm

Brief summary

This proof-of-concept study will evaluate whether physiologic pacemaker programming improves cognitive function and health status in patients with symptomatic bradycardia who require permanent pacemaker implantation. Participants will be randomized to either standard pacemaker programming at 60 beats per minute or individualized physiologic rate pacing between 60 and 90 beats per minute using the myPACE algorithm. Cognitive function and health status will be assessed before pacemaker implantation and again at the routine 3-month pacemaker clinic visit. The primary outcome is change in Montreal Cognitive Assessment total score. The secondary outcome is change in SF-36 mental component summary score.

Detailed description

Cardiac pacing may improve cognition by restoring physiologic heart rates, enhancing cerebral perfusion, and improving overall cardiovascular function in patients with symptomatic bradycardia who require permanent pacemaker implantation. In current clinical practice, the lower pacing rate is commonly programmed to 60 beats per minute, which is below the normal resting heart rate in many adults. PACE Cognition is a proof-of-concept study evaluating the impact of physiologic pacemaker programming on cognitive function and health status. Patients requiring permanent pacemaker implantation for bradycardia will be screened before device implantation. Interested and eligible patients will provide written informed consent before any study-specific procedures are performed. Baseline cognitive and health-status assessments will be completed before pacemaker implantation. Cognitive function will be assessed using the Montreal Cognitive Assessment, a brief standardized screening instrument that evaluates multiple cognitive domains, including memory, attention, language, visuospatial ability, executive function, and orientation. Health status and functional well-being will be assessed using the SF-36 questionnaire, including the mental component summary score. Participants will be randomized to either standard pacing at 60 beats per minute or individualized physiologic rate pacing between 60 and 90 beats per minute using the myPACE algorithm. Follow-up Montreal Cognitive Assessment and SF-36 assessments will be repeated at the routine 3-month pacemaker clinic visit to evaluate changes in cognitive performance and health status between the pacing strategies.

Interventions

DEVICEPhysiologic Pacemaker Programming

Individualized physiologic pacemaker programming between 60 and 90 beats per minute will be performed using the myPACE algorithm.

DEVICEStandard Pacemaker Programming

Standard pacemaker programming with a lower pacing rate of 60 beats per minute will be used after permanent pacemaker implantation.

Sponsors

University of Minnesota
Lead SponsorOTHER
Medtronic
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants requiring permanent pacemaker implantation for bradycardia will be randomized to standard pacing at 60 beats per minute or individualized physiologic rate pacing between 60 and 90 beats per minute using the myPACE algorithm. Cognitive function and health status will be assessed before pacemaker implantation and at the routine 3-month pacemaker clinic visit.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Patient requiring a pacemaker for bradycardia

Exclusion criteria

* Vulnerable adult unable to give consent * Unable to answer questionnaire * Children * Pregnant women/persons * Prisoners * Adults lacking capacity to consent or adults with diminished or fluctuating capacity to consent * Non-English speakers * Individuals unable to read * Employees or students of the researcher * Active members of the military or DoD personnel

Design outcomes

Primary

MeasureTime frameDescription
Change in Montreal Cognitive Assessment Total ScoreBaseline to 3 months after pacemaker implantationChange in Montreal Cognitive Assessment total score from baseline to 3 months after pacemaker implantation will be compared between participants randomized to standard pacemaker programming at 60 beats per minute and participants randomized to physiologic pacemaker programming between 60 and 90 beats per minute using the myPACE algorithm. The Montreal Cognitive Assessment is scored from 0 to 30, with higher scores indicating better cognitive function.

Secondary

MeasureTime frameDescription
Change in Short Form 36 Health Survey Mental Component Summary ScoreBaseline to 3 months after pacemaker implantationChange in Short Form 36 Health Survey Mental Component Summary score from baseline to 3 months after pacemaker implantation will be compared between participants randomized to standard pacemaker programming at 60 beats per minute and participants randomized to physiologic pacemaker programming between 60 and 90 beats per minute using the myPACE algorithm. The Short Form 36 Health Survey Mental Component Summary score ranges from 0 to 100, with higher scores indicating better mental health and psychological well-being.

Countries

United States

Contacts

CONTACTMarkus Meyer, MD
markusmeyermd@gmail.com802-922-0656
CONTACTSamantha Wansing
hoppx054@umn.edu
PRINCIPAL_INVESTIGATORSelma Carlson, MD

University of Minnesota

PRINCIPAL_INVESTIGATORMarkus Meyer, MD

University of Minnesota

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026